Funded Startups in Allschwil
Recent rounds in Allschwil skew heavily toward a single disclosed outlier: Cancentus’ $640K (2026-04-26) is the largest disclosed amount in this 5-row slic…
Recent rounds in Allschwil skew heavily toward a single disclosed outlier: Cancentus’ $640K (2026-04-26) is the largest disclosed amount in this 5-row slice, and it sits far above the next-highest disclosed rounds of $3M (Spexis, 2023-08-15 and Polyphor, 2020-11-24) and $26M (Synendos Therapeutics, 2021-04-20). Sector clustering is also clear, with all five entries tied to the Allschwil address and four of five companies operating in Biotechnology (Cancentus, BaseLaunch, Spexis, Polyphor) versus one in Health Care (Synendos Therapeutics). Temporally, the data spans from 2020-11-24 to the newest 2026-04-26, but only one entry falls after 2024 (Cancentus in 2026 and BaseLaunch in 2024). Stage labeling is sparse: four of five rows use “Series Unknown,” and one row is specifically “Series A” (Synendos Therapeutics, 2021-04-20, $26M), with one “undisclosed” amount (BaseLaunch, 2024-05-22).
Most recent rounds
5 shownRelated listings
Frequently asked
What’s the largest disclosed round in this Allschwil set, and how concentrated are the other disclosed amounts?
Cancentus’ $640K on 2026-04-26 is the largest disclosed amount among the five rows; the remaining disclosed amounts cluster at $3M (Spexis on 2023-08-15 and Polyphor on 2020-11-24) plus $26M for Synendos Therapeutics on 2021-04-20, while BaseLaunch is “undisclosed” on 2024-05-22.
Do these entries cluster in time, or are they spread across multiple funding eras?
They span 2020-11-24 (Polyphor) through 2026-04-26 (Cancentus), but only one record appears in the 2024–2026 window besides BaseLaunch (2024-05-22) and Cancentus (2026-04-26). Between 2020 and 2023, Biotechnology rounds show up at 2020-11-24, 2023-08-15, with Synendos Therapeutics’ 2021-04-20 Series A in the middle.
Is Biotechnology over-represented compared with Health Care in this city slice?
Yes: four of five companies are listed in Biotechnology (Cancentus, BaseLaunch, Spexis, Polyphor), while only one is in Health Care (Synendos Therapeutics on 2021-04-20). That 4/5 split is reinforced by the fact that the non-Biotechnology entry is the only clearly labeled “Series A” row.
How much of the stage information is missing or unclear here?
Stage classifications are predominantly unclear: four of five rows show “Series Unknown,” and one row is “Series A” (Synendos Therapeutics, $26M on 2021-04-20). Separately, one company lists the amount as “undisclosed” (BaseLaunch on 2024-05-22), limiting comparisons of disclosed size.
Are there any notable outliers worth focusing on for follow-up outreach?
BaseLaunch is an information outlier on both fields: its 2024-05-22 round is “Series Unknown” with an “undisclosed” amount, making it hard to benchmark size. On disclosed amounts, the spread is driven by Synendos Therapeutics’ $26M (2021-04-20) versus the $3M Biotechnology rounds at 2023-08-15 (Spexis) and 2020-11-24 (Polyphor).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.